Search for a trial

Protocol CKI-302 KW-3902IV in the treatment of subjects with acute heart failure syndrome
A multicenter, randomized, double-blind, placebo-controlled study of the effects of KW-3902 injectable emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalized for volume overload and require intravenous diuretic therapy

To evaluate the effect of KW-3902IV in addition to IV loop diuretic therapy on heart failure signs and symptoms, persistent renal dysfunction, morbidity and mortality, and safety in subjects hospitalized with acute heart failure syndrome, volume…

Double blind placebo controlled study on the efficacy of melatonin on sleep parameters and quality of life in hemodialysis patients

Does melatonin by improving sleep parameters improve quality of life of hemodialysis patients?

Inflammation, overhydration, and silent coronary ischemia in dialysis patients: a longitudinal cohort study

Aim of the present study is to test the hypothesis tha during inflammatory episodes there is a decline in lean body and fat mass and that this results in an increase in extracellular volume in dialysis patients because dry weight is not or…

Systemic Levels of Cystatin C in Critically Ill Patients with Acute Renal Failure Requiring Hemofiltration.

To evaluate whether (changes in) systemic CysC-concentration can be used as a marker for improvement of the renal function in critically ill patients while treated with HF.

Anti-inflammatory effects of rosiglitazone in patients with stage 4 and 5 chronic kidney disease

The primary aim of this study will be to determine the effect of rosiglitazone on intima media thickness and calcification in patients with stage 4 and 5 CKD. The secondary end points are the effects on pulse wave velocity, blood pressure, the lipid…

A twelve-month, multicenter, open-label, randomized study of the safety, tolerability and efficacy of Certican* with Simulect, corticosteroids and two different exposure levels of tacrolimus in de novo renal transplant recipients

With the goal of improving kidney function and without causing an increased number of rejections, is it possible to reduce tacrolimus dosage through the use of the previously-mentioned immunosupressives after month three.

Systemic Levels of Cystatin C in Critically Ill Patients at risk for Acute Renal Failure.

To evaluate whether (changes in) serum CysC concentration can be used as a marker of renal function in a large cohort of critically ill patients, and to describe the kinetics of CysC in these patients.

An international, randomised, open label trial comparing a rituxmab based regimen with a standard cyclophosphamide/azathioprine regimen in the treatment of active, 'generalised' ANCA associated vasculitis

To assess the rates of preliminary response and sustained remission of AASV following rituximab (on the basis of former studies, 86% sustained remission expected with rituximab compared to 75% in control group).To assess safety of a rituximab…

Anticoagulation with nadroparin in continuous venovenous hemofiltration (CVVH): extracorporeal clearance and systemic effects of nadroparin

Aim of the present study is to determine · whether and to what extent nadroparin is excreted by CVVH · whether the drug accumulates during CVVH as measured by anti-Xa activity and endogenous thrombine potential (ETP)· whether clearance of nadroparin…